Business Context and Reporting Period
Company: Novo Nordisk A/S
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: October 21, 2024
Subject: Update on Share Repurchase Programme
Novo Nordisk is a leading global healthcare company headquartered in Denmark, employing approximately 69,000 people across 80 countries. The filing reports on the execution of a share repurchase programme initiated on August 7, 2024, which is part of a broader authorization to repurchase up to DKK 20 billion over a 12-month period starting February 6, 2024.
Key Financial Metrics
This filing focuses on capital allocation activities rather than operational financial performance. Key metrics related to the share repurchase programme include:
- Programme Authorization: Up to DKK 20 billion (12-month period from Feb 6, 2024).
- Specific Sub-Programme (Aug 7 - Nov 4, 2024): Up to DKK 2.4 billion.
- Total Repurchased (Since Feb 6, 2024): 13,363,648 B shares.
- Total Value Repurchased (Since Feb 6, 2024): DKK 11,715,501,874.
- Average Price (Since Feb 6, 2024): DKK 876.67 per B share.
- Treasury Shares Held: 14,692,279 B shares (0.3% of share capital).
Note: The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Recent Activity
The filing details specific transactions executed between October 14 and October 18, 2024, under the August 7 sub-programme:
- Transactions: Five consecutive daily purchases of 46,000 B shares each.
- Price Range: Average purchase prices ranged from DKK 803.95 to DKK 817.40.
- Accumulated Value (Sub-Programme): DKK 1,987,795,825 (as of Oct 18, 2024).
- Accumulated Shares (Sub-Programme): 2,296,522 B shares.
Guidance, Outlook, and Risks
Outlook: Novo Nordisk expects to continue repurchasing B shares up to the total authorized amount of DKK 20 billion during the 12-month period beginning February 6, 2024. As of October 18, 2024, approximately 58.6% of the total authorized amount has been utilized.
Risks and Contingencies: The filing does not disclose new material risks or contingencies. It references compliance with the EU Market Abuse Regulation (MAR) and Safe Harbour Rules.
Investor Verification Checklist
- Verify the remaining capacity of the DKK 20 billion share repurchase programme (approx. DKK 8.29 billion remaining).
- Confirm the current market price of Novo Nordisk B shares relative to the recent average repurchase price of DKK 876.67.
- Review the full list of daily transactions on the company's official website (novonordisk.com) for updates beyond October 18, 2024.
- Check the latest Form 20-F or quarterly reports for operational financial metrics (revenue, profit, cash flow) not included in this 6-K filing.